Vyluma is a private biopharmaceutical company focused on developing novel topical treatments (eye drops) to address significant unmet needs for ophthalmic diseases that are prevalent worldwide.
The Vyluma team is committed to developing and commercializing transformative therapeutics to preserve patients’ vision and improve their quality of life. In partnership with eye care clinicians, we are driven to transform the current standard of care with a promising pipeline of novel candidates.
Our pipeline programs are designed to preserve visual function, prevent blindness, and restore patients’ quality of life.
Vyluma’s leading pipeline candidate, NVK002 for myopia, if approved, will be the first pharmaceutical product to slow the progression of myopia in children.
Quality of Life through Vision Improvement
Myopia is the leading cause of preventable blindness worldwide. It is estimated that by 2050 there will be approximately 5 billion people with myopia (50% of the world’s population).
NVK002 is a low-dose atropine eye drop using Vyluma’s proprietary technology to slow the progression of myopia in children. If approved, it would be the first pharmaceutical treatment for myopia.
Estimated to affect more than 110 million adults in the United States, presbyopia impairs a patient’s ability to focus on objects at near or intermediate distances.
NVK029 is an alternative to spectacles or contact lenses being developed by Vyluma. It is currently in phase II and, if approved, would be accessible to patients as an OTC therapy.
Night Vision Disturbance
Those effected by night vision disturbance symptoms have difficulty seeing in dark conditions, especially while driving. The most frequent night vision disturbances include blurry vision, difficulty seeing objects at a distance, or glare/halos.
Vyluma’s NVK031 program showed reduction in pupil size by 1mm-2mm, which reduced symptoms of glare, in its proof-of-concept clinical study.